1 July 2014 in European Urology
29 March 2019 in BJU International
1 March 2014 in European Journal of Cancer
28 September 2011 in International Journal of Oncology
Most tissue microarray studies have used a single 0.6-mm tissue core per donor tissue. It has been suggested that multiple cores per donor can increase the representativity of tissue microarray studies. To estimate the potential benefit of multiple cores, we analyzed Ki67 and p53 in triplet cores taken from three different areas of 3,261 prostate cancer tissue blocks. Both p53 and Ki67 labeling index were linked to advanced tumor stage (p<0.0001 each), Gleason score (p<0.0001), and early PSA recurrence (p<0.0001) independently of whether the 3 tissue spots were analyzed separately or combined for a consensus result. The rate of positive findings increased with the amount of analyzed tissue. The average Ki67 labeling index was higher in tumors with 3 interpretable spots (5.3±5.6) as compared to two (4.1±4.7) or one interpretable spot (4.1±4.2, p<0.0001). For p53, tumors with three interpretable spots were positive in 3.8% of cases, and tumors with 1 or 2 interpretable spots in 1.9% only (p=0.003). These data demonstrate that using multiple cores in a tissue microarray does not necessarily increase the ability to identify associations of biomarkers with tumor phenotype and prognosis but has always the disadvantage of additional work and tissue requirements. Multiple cores may even lead to statistical problems if unequal amounts of tissue are analyzed per tumor.
17 August 2016 in BMC Cancer
TMPRSS2:ERG fusions are frequent in prostate cancer, and occur predominantly in young patients. Several studies had proposed intratumoral heterogeneity of these fusions. This study was designed to determine frequency and extent of ERG fusion heterogeneity in early-onset prostate cancer (EO-PCA, <50 years) and in elderly patients. The prostates from 63 EO-PCA and 62 elderly prostate cancer patients were thoroughly reviewed for presence of cancer foci. All 1592 tumor-containing sections were analyzed by immunohistochemistry for ERG expression. The prostates included in this study contained one tumor focus in 44, two tumor foci in 21, three tumor foci in 32, four tumor foci in 15, and five or more tumor foci in 13 patients. Among 59 cancer foci with ≤3 mm, 19 (32.2 %) were homogeneously ERG positive, 39 66.1 %) were homogeneously ERG negative, and one case (1.7 %) showed a heterogeneous ERG status. The fraction of homogeneously ERG positive cancer foci remained largely constant (14–37 %) with increasing tumor focus diameter but the fraction of heterogeneous ERG findings continuously increased with tumor size and reached 39 % in cancer foci larger than 22 mm. On a patient level, ERG expression was markedly more frequent in EO-PCA than in elderly patients: 13 % of EO-PCA were homogeneously and 62 % were heterogeneously ERG positive. In elderly patients, 3 % of cancers were homogeneously and 57 % were heterogeneously ERG positive (p = 0.0721). These data show that about 20–30 % of prostate cancer foci have early ERG fusions. ERG fusions further occur in about 50 % of initially ERG negative cancer foci during cancer progression. The vast majority of cancers are heterogeneous for TMPRSS2:ERG fusions on a patient level, challenging the concept of classifying prostate cancer patients into “fusion type” and “non-fusion type” prostate cancer.
3 February 2003 in Cancer